Ferrarini M, Heltai S, Pupa S M, Mernard S, Zocchi R
Laboratori Immunoterapia Adottiva, Istituto Scientifico H.S. Raffaele.
J Natl Cancer Inst. 1996 Apr 3;88(7):436-41. doi: 10.1093/jnci/88.7.436.
The monomeric laminin receptor, a 67-kd high-affinity laminin-binding protein, is expressed by a variety of normal cell types. Overexpression and abnormal surface distribution of this receptor have been demonstrated in tumor cells where it appears to promote tumor invasion and metastasis. Previously, we reported the existence of an association between laminin receptor overexpression by lung cancer cells and the presence of tumor-infiltrating lymphocytes (TILs) bearing gammadelta T-cell receptors. Gammadelta(+) lymphocytes represents a sizable fraction of the TILs in approximately one fourth of lung cancers analyzed thus far.
The aim of this study was to determine whether gammadelta(+) TILs might participate in the immune response against lung cancer through recognition of monomeric laminin receptors expressed by tumor cells.
Tumor cells from 11 lung cancer specimens exhibiting sizable gammadelta(+) T-cell infiltrates and from 11 other specimens infiltrated predominantly by lymphocytes bearing alphabeta(+) T-cell receptors were analyzed for expression of the monomeric laminin receptor by use of the monoclonal antibody (MAb) MLuC5. Gammadalta TILs and chibeta+ TILs derived from four tumors were each examined for cytotoxic activity toward lung cancer target cells by use of a standard 51Cr-release assay and lung tumor cell lines expressing different levels of surface monomeric laminin receptor. The ability of MAbs directed against the laminin receptor (i.e., MLuC5) or against gammadelta T-cell receptors (i.e., TigammaA and A13) as well as laminin peptides known to bind to the laminin receptor to inhibit TIL-mediated target cells lysis was also determined.
We confirmed that the association between overexpression of the monomeric laminin receptor by lung tumor cells and the presence of gammadeltadelta+ TILs is statistically significant (two sided P = .003; Fisher's exact test). We also observed a relationship between the levels of laminin receptor expression on cultured lung cancer cells and their susceptibility to specific lysis by gammadelta(+), but not alphabeta+, TILs. This specific cell killing was not T-cell receptor mediated, but it was inhibited by addition of the anti-monomeric laminin receptor MAb MLuC5 and by a synthetic peptide corresponding to amino acids 2091-2108 of the laminin A chain.
Our results indicate gammadelta(+) TILs localized at human lung cancer sites can kill tumor cells in a process that involves interaction with the monomeric laminin receptor. The infiltration of gammadelta(+) TILs at lung tumor sites may represent a first line of defense against cells undergoing malignant transformation.
单体层粘连蛋白受体是一种67kd的高亲和力层粘连蛋白结合蛋白,由多种正常细胞类型表达。该受体在肿瘤细胞中过表达且表面分布异常,似乎促进肿瘤侵袭和转移。此前,我们报道了肺癌细胞层粘连蛋白受体过表达与携带γδT细胞受体的肿瘤浸润淋巴细胞(TILs)的存在之间存在关联。在迄今为止分析的约四分之一的肺癌中,γδ(+)淋巴细胞占TILs的相当一部分。
本研究的目的是确定γδ(+)TILs是否可能通过识别肿瘤细胞表达的单体层粘连蛋白受体参与针对肺癌的免疫反应。
使用单克隆抗体(MAb)MLuC5分析来自11个表现出大量γδ(+)T细胞浸润的肺癌标本以及来自11个主要由携带αβ(+)T细胞受体的淋巴细胞浸润的其他标本的肿瘤细胞中单体层粘连蛋白受体的表达。使用标准的51Cr释放试验和表达不同水平表面单体层粘连蛋白受体的肺癌细胞系,检测来自四种肿瘤的γδTILs和αβ+TILs对肺癌靶细胞的细胞毒性活性。还确定了针对层粘连蛋白受体的单克隆抗体(即MLuC5)或针对γδT细胞受体的单克隆抗体(即TigammaA和A13)以及已知与层粘连蛋白受体结合的层粘连蛋白肽抑制TIL介导的靶细胞裂解的能力。
我们证实肺癌细胞单体层粘连蛋白受体过表达与γδδ+TILs的存在之间的关联具有统计学意义(双侧P = 0.003;Fisher精确检验)。我们还观察到培养的肺癌细胞上层粘连蛋白受体表达水平与其对γδ(+)而非αβ+TILs特异性裂解的敏感性之间的关系。这种特异性细胞杀伤不是由T细胞受体介导的,但可通过添加抗单体层粘连蛋白受体单克隆抗体MLuC5和对应于层粘连蛋白A链氨基酸2091 - 2108的合成肽来抑制。
我们的结果表明,定位于人肺癌部位的γδ(+)TILs可通过与单体层粘连蛋白受体相互作用的过程杀伤肿瘤细胞。γδ(+)TILs在肺肿瘤部位的浸润可能代表针对发生恶性转化细胞的第一道防线。